<DOC>
	<DOCNO>NCT01884129</DOCNO>
	<brief_summary>We hypothesize number circulate tumor cell ( CTCs ) molecular marker CTCs could prognostic factor predictive factor patient head neck cancer .</brief_summary>
	<brief_title>Prognostic Value CTC HNSCC Patients</brief_title>
	<detailed_description>1 . Histologically cytopathologically proven head neck squamous cell carcinoma ( HNSCC ) 2 . Disease status : locally advance recurrent/metastasized initial presentation 3 . Age &gt; =20 year old 4 . Could understand sign informed consent study 5 . Enrolled patient classify three distinct subgroup : 1 . Patients underwent curative surgery follow adjuvant chemoradiotherapy ( CRT ) pathologic feature positive margin , pathologic N2 , extracapsular spread ( ECS ) involve lymph node indicate early relapse accord recommendation National Comprehensive Cancer Network ( NCCN ) guideline ; 2 . Patients advanced disease directly underwent definitive concurrent chemoradiotherapy ( CCRT ) ; 3 . Patients palliative chemotherapy existence distant metastasis poor general condition definitive CCRT . 6 . Blood sample collect within 7 day first dose chemotherapy .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>histologically cytopathologically proven head neck squamous cell carcinoma Age â‰¥ 20 year . Measurable evaluable disease accord Response Evaluation Criteria In Solid Tumors ( RECIST ) criterion . Ability sign inform consent . Prior cancer within 5 year , except nonmelanoma skin cancer , situ cervical cancer . Inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Circulating tumor cell</keyword>
	<keyword>Head neck cancer</keyword>
	<keyword>Squamous cell carcinoma</keyword>
	<keyword>Survival</keyword>
	<keyword>Prognosis</keyword>
</DOC>